Abstract
Importance COVID-19 vaccination is recommended during pregnancy for the protection of the mother. Little is known about the immune response to booster vaccinations during pregnancy.
Objective To measure immune responses to COVID-19 primary and booster mRNA vaccination during pregnancy and transplacental antibody transfer to the newborn.
Design Prospective cohort study of pregnant participants enrolled from July 2021 to January 2022, with follow up through and up to 12 months after delivery.
Setting Multicenter study conducted at 9 academic sites.
Participants Pregnant participants who received COVID-19 vaccination during pregnancy and their newborns.
Exposure(s) Primary or booster COVID-19 mRNA vaccination during pregnancy.
Main Outcome(s) and Measure(s) SARS-CoV-2 binding and neutralizing antibody (nAb) titers after primary or booster COVID-19 mRNA vaccination during pregnancy and antibody transfer to the newborn. Immune responses were compared between primary and booster vaccine recipients in maternal sera at delivery and in cord blood, after adjusting for days since last vaccination.
Results In this interim analysis, 167 participants received a primary 2-dose series and 73 received a booster dose of mRNA vaccine during pregnancy. Booster vaccination resulted in significantly higher binding and nAb titers, including to the Omicron BA.1 variant, in maternal serum at delivery and cord blood compared to a primary 2-dose series (range 0.55 to 0.88 log10 higher, p<0.0001 for all comparisons). Although levels were significantly lower than to the prototypical D614G variant, nAb to Omicron were present at delivery in 9% (GMT ID50 12.7) of Pfizer and 22% (GMT ID50 14.7) of Moderna recipients, and in 73% (GMT ID50 60.2) of boosted participants (p<0.0001). Transplacental antibody transfer was efficient regardless of vaccination regimen (median transfer ratio range: 1.55-1.77 for binding IgG and 1.00-1.78 for nAb).
Conclusions and Relevance COVID-19 mRNA vaccination during pregnancy elicited robust immune responses in mothers and efficient transplacental antibody transfer to the newborn. A booster dose during pregnancy significantly increased maternal and cord blood antibody levels, including against Omicron.
Findings support continued use of COVID-19 vaccines during pregnancy, including booster doses.
Trial Registration clinical trials.gov; Registration Number: NCT05031468; https://clinicaltrials.gov/ct2/show/NCT05031468
Question What is the immune response after COVID-19 booster vaccination during pregnancy and how does receipt of a booster dose impact transplacental antibody transfer to the newborn?
Findings Receipt of COVID-19 mRNA vaccines during pregnancy elicited robust binding and neutralizing antibody responses in the mother and in the newborn. Booster vaccination during pregnancy elicited significantly higher antibody levels in mothers at delivery and cord blood than 2-dose vaccination, including against the Omicron BA.1 variant.
Meaning COVID-19 vaccines, especially booster doses, should continue to be strongly recommended during pregnancy.
Competing Interest Statement
F.M.M. is an investigator of pediatric studies of COVID-19 vaccines for Pfizer and for a pediatric remdesivir study conducted by Gilead Sciences Inc F.M.M. serves as investigator on projects supported by an NIH contract for a Vaccine Treatment and Evaluation Unit (VTEU) F.M.M. serves as member of the Data Safety monitoring Board (DSMB) for clinical trials conducted by Pfizer Moderna Meissa Vaccines Virometix and the NIH F.M.M. is a member of the American Academy of Pediatrics Committee of Infectious Diseases (COID) and the Immunization Expert Group of the American College of Obstetrics and Gynecology (ACOG) and Co-Chair of the COVAX Maternal Immunization Working Group. K.M.N. is a member of the World Health Organization (WHO) Strategic Advisory Group of Experts on Immunization. K.M.N. serves as co-investigator on an NIH contract for a Vaccine Treatment and Evaluation Unit (VTEU). K.M.N. serves as Co-chair of the NIH COVID Prevention Network (CoVPN) and served as an investigator for Phase I/II Pfizer COVID-19 vaccine grant with a grant to the institution but no salary support. K.M.N. receives grants from Pfizer to conduct clinical trials of COVID vaccines through the Center for Vaccine Development and Global Health at University of Maryland in Baltimore. She receives grants from NIH to participate in overall organization of COVID-19 vaccine trials and for participation in vaccine trials. M.J.M. conducts laboratory research and clinical trials with contract funding for vaccines or MABs vs SARS-CoV-2 with Lilly and Pfizer and Sanofi and receives personal fees for Scientific Advisory Board service from Merck Meissa Vaccines Inc. and Pfizer. M.S.S. served as an advisor for Moderna (ended December 2021) and is currently serving as an advisor for Ocugen Inc. B.A.R. currently holds a position on a DSMB for clinical trials at Gilead Sciences Inc. R.C.B. at Cincinnati Childrens Hospital receives research grant support for clinical trials from PATH and Astra Zeneca and Pfizer on which she serves as co-investigator. B.B. owns shares in HDT Bio Corp. J.S.G. receives research funds from NIH for Moderna KidCOVE study. R.M.N. is a paid advisor to Gilead and an investigator on NIH-funded trials of Moderna and Pfizer and Janssen vaccines. J.R.K. is a medical speaker for Abbott Nutrition with the UIC team. A.R.F. holds research grants from Pfizer and Janssen and Merck and Cyanvac and Biofire Diagnostics and serves on the DSMB for Novavax. N.R. receives funds to conduct industry trials from Pfizer and Merck and Sanofi-Pasteur and serves as a safety consultant for EMMES and ICON. R.W.F. Jr. has received funds to conduct industry trials from Pfizer and Moderna and Astra Zeneca and serves on advisory boards for Merck and Sanofi-Pasteur and Johnson and Johnson and Seqirus and serves on an ICON-sponsored DSMB for a C difficile study.
Funding Statement
Supported by the Infectious Diseases Clinical Research Consortium (IDCRC) through the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health (NIH), under award numbers UM1AI148684, UM1AI148575, UM1AI148372, UM1AI148452, UM1AI148576, UM1AI148574, UM1AI148450, UM1AI148685, UM1AI148689, and UM1AI148373. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval of this protocol was received on May 28, 2021 by Vanderbilt University Medicine Center IRB, a single IRB as part of an NIH-funded consortium, IDCRC. Written informed consent was obtained from each participant.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵17 DMID 21-0004 Study Group
cposavad{at}fredhutch.org
barbrar{at}uw.edu
mbadell{at}emory.edu
bungke{at}upmc.edu, beigrh{at}upmc.edu
mark.mulligan{at}nyulangone.org, lalitha.parameswaran{at}nyulangone.org
cwkelly{at}scharp.org, skim234{at}scharp.org
courtney_olson-chen{at}urmc.rochester.edu
rmnovak{at}uic.edu
rebecca.brady{at}cchmc.org, defranee{at}ucmail.uc.edu
mpasetti{at}som.umaryland.edu, mallory.shriver{at}som.umaryland.edu, kneuzil{at}som.umaryland.edu
gerberj{at}chop.edu
mehul.s.suthar{at}emory.edu, kathryn.moore2{at}emory.edu
Rhea.Coler{at}seattlechildrens.org, Bryan.Berube{at}seattlechildrens.org
piperj{at}niaid.nih.gov, cristina.cardemil{at}nih.gov
amiller{at}fhi360.org
Data Availability
Data collected for the study will be made available to others as a de-identified patient data set after finalization of clinical study report at the discretion of the IDCRC. Analyses of data, including data from staged analyses, will be available for presentation at scientific meetings and publication to inform the scientific community. If preliminary analyses are considered of public health importance or relevant to inform research, development, and implementation of SARS-CoV-2 vaccine in pregnancy, results may be shared with public health officials and partners to inform the global scientific community. The study will be conducted in accordance with the NIH Public Access Policy publication and data sharing policies and regulations. To request study data once complete, contact Flor M. Munoz, florm{at}bcm.edu
List of Abbreviations
- ACOG
- American College of Obstetricians and Gynecologists
- BAU/mL
- Binding Antibody Units
- CoVPN
- COVID Prevention Network
- DMID
- Division of Microbiology and Infectious Diseases
- DSMB
- Data Safety monitoring Board
- FRNT
- Focus reduction neutralization titer
- GMT
- Geometric mean titer
- IDCRC
- Infectious Diseases Clinical Research Consortium
- IgG
- Immunoglobulin G
- IQRs
- Interquartile ranges
- MSD
- Meso Scale Discovery
- nAb
- Neutralizing antibodies
- NIH
- National Institutes of Health
- RBD
- Receptor binding domain
- Spike
- Full-length spike
- U.S.
- United States
- VTEU
- Vaccine Treatment and Evaluation Unit
- WHO
- World Health Organization
